Your browser is no longer supported. Please, upgrade your browser.
Settings
MGEN Miragen Therapeutics, Inc. daily Stock Chart
MGEN [NASD]
Miragen Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own10.65% Shs Outstand30.16M Perf Week0.85%
Market Cap71.48M Forward P/E- EPS next Y-1.44 Insider Trans0.00% Shs Float27.66M Perf Month-12.55%
Income-39.70M PEG- EPS next Q-0.37 Inst Own45.20% Short Float5.77% Perf Quarter-20.47%
Sales4.00M P/S17.87 EPS this Y19.80% Inst Trans-9.51% Short Ratio9.55 Perf Half Y-7.06%
Book/sh1.33 P/B1.78 EPS next Y-1.40% ROA-56.80% Target Price15.10 Perf Year-65.04%
Cash/sh1.69 P/C1.40 EPS next 5Y- ROE-71.90% 52W Range2.01 - 7.94 Perf YTD-21.78%
Dividend- P/FCF- EPS past 5Y36.20% ROI-53.70% 52W High-70.15% Beta1.28
Dividend %- Quick Ratio7.90 Sales past 5Y14.20% Gross Margin- 52W Low17.91% ATR0.19
Employees81 Current Ratio7.90 Sales Q/Q-91.70% Oper. Margin- RSI (14)45.81 Volatility5.54% 8.44%
OptionableNo Debt/Eq0.25 EPS Q/Q-113.90% Profit Margin- Rel Volume0.69 Prev Close2.43
ShortableYes LT Debt/Eq0.17 EarningsMay 08 AMC Payout- Avg Volume166.97K Price2.37
Recom1.20 SMA20-0.38% SMA50-10.95% SMA200-31.07% Volume119,463 Change-2.47%
Jan-04-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $18.50
Mar-29-18Initiated Jefferies Buy $14
Mar-09-18Initiated Evercore ISI Outperform $19
Jan-05-18Initiated B. Riley FBR, Inc. Buy $15.50
Jun-21-19 01:45PM  Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop Simply Wall St.
May-28-19 04:30PM  miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference GlobeNewswire -6.12%
May-21-19 07:00AM  miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference GlobeNewswire
May-08-19 06:35PM  Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:01PM  miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-01-19 10:32AM  Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline Zacks -5.80%
Apr-29-19 07:00AM  miRagen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen to Prevent Corneal Fibrosis at the 2019 ARVO Meeting GlobeNewswire
Apr-28-19 10:42AM  Can We See Significant Institutional Ownership On The Miragen Therapeutics, Inc. (NASDAQ:MGEN) Share Register? Simply Wall St.
Apr-26-19 07:00AM  miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru GlobeNewswire +7.25%
Apr-25-19 08:00AM  miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th GlobeNewswire
Mar-14-19 11:48PM  Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-13-19 05:40PM  Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:05PM  miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook GlobeNewswire
Mar-06-19 08:00AM  miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference GlobeNewswire -7.34%
Feb-20-19 08:00AM  miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th GlobeNewswire
Jan-24-19 09:05AM  Colorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweating American City Business Journals
Jan-10-19 07:00AM  miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen GlobeNewswire -15.75%
Dec-20-18 07:00AM  miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum GlobeNewswire
Dec-18-18 10:11AM  Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN) Insider Monkey
Dec-05-18 04:05PM  miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman GlobeNewswire
Dec-02-18 05:00PM  miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides GlobeNewswire
Nov-07-18 06:40PM  Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 09:00AM  Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting GlobeNewswire +7.18%
Oct-29-18 07:00AM  miRagen Therapeutics to Present at two Investor Conferences in November 2018 GlobeNewswire
Oct-24-18 07:00AM  miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018 GlobeNewswire -6.39%
Oct-01-18 07:00AM  miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA GlobeNewswire
Aug-07-18 04:05PM  miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Miragen Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 07:00AM  miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma GlobeNewswire
Jul-31-18 07:00AM  miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-25-18 07:00AM  miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018 GlobeNewswire
Jul-10-18 07:00AM  miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201 GlobeNewswire -5.28%
Jul-03-18 12:38PM  Gaithersburg biotech raising $1M to stop cancer tumors in their tracks American City Business Journals
Jun-04-18 07:30AM  Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-31-18 07:00AM  miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th GlobeNewswire
May-16-18 05:00PM  miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-09-18 04:05PM  miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 09:23PM  Should Miragen Therapeutics Incs (NASDAQ:MGEN) Recent Earnings Decline Worry You? Simply Wall St.
04:05PM  miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides GlobeNewswire
May-02-18 04:05PM  miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases GlobeNewswire +5.08%
07:00AM  miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018 GlobeNewswire
May-01-18 07:00AM  miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110 GlobeNewswire
Apr-30-18 04:05PM  miRagen Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Apr-27-18 07:00AM  miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies GlobeNewswire
Apr-19-18 07:00AM  miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings GlobeNewswire
Mar-27-18 07:00AM  miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110 GlobeNewswire -6.52%
Mar-20-18 07:00AM  Blog Exposure - Foundation Medicine Collaborated with Chugai for Commercialization of FoundationOne CDx(TM) in Japan ACCESSWIRE
Mar-14-18 04:05PM  miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:00PM  Miragen Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 07:00AM  miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018 GlobeNewswire
Mar-05-18 07:00AM  miRagen Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.85%
Feb-08-18 06:45PM  miRagen Therapeutics, Inc. Prices Public Offering of Common Stock GlobeNewswire -6.72%
Feb-05-18 06:05AM  miRagen Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -9.88%
Feb-02-18 07:00AM  miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum GlobeNewswire +7.77%
Jan-24-18 07:00AM  miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum GlobeNewswire
Jan-12-18 01:21PM  Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst Benzinga
Jan-05-18 04:10PM  Where Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St. -6.47%
07:00AM  miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris GlobeNewswire
Dec-28-17 04:45PM  Miragen Therapeutics Inc (NASDAQ:MGEN): Will The Growth Last? Simply Wall St.
08:46AM  Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions? Zacks
Dec-21-17 11:36AM  ETFs with exposure to Miragen Therapeutics, Inc. : December 21, 2017 Capital Cube
Dec-11-17 04:05PM  miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting GlobeNewswire
Nov-14-17 02:34PM  ETFs with exposure to Miragen Therapeutics, Inc. : November 14, 2017 Capital Cube
Nov-13-17 09:57AM  Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube -7.50%
Nov-08-17 04:05PM  miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:50PM  Miragen Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-17 04:05PM  miRagen Therapeutics to Participate in Four Investor Conferences in November GlobeNewswire
Nov-01-17 04:05PM  miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017 GlobeNewswire
09:00AM  miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting GlobeNewswire
Oct-18-17 07:00AM  miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference GlobeNewswire
Oct-16-17 07:00AM  Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106 ACCESSWIRE
Oct-13-17 07:00AM  miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting GlobeNewswire
Oct-03-17 11:24AM  ETFs with exposure to Miragen Therapeutics, Inc. : October 3, 2017 Capital Cube
07:00AM  miRagen Therapeutics to Present at the Chardan Inaugural Gene Therapy Conference GlobeNewswire
Sep-19-17 06:00PM  ETFs with exposure to Miragen Therapeutics, Inc. : September 19, 2017 Capital Cube
07:00AM  miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-18-17 01:25PM  Miragen Therapeutics, Inc. :MGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-11-17 04:05PM  miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis GlobeNewswire
Sep-01-17 07:00AM  Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress GlobeNewswire
Aug-11-17 04:05PM  miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Aug-08-17 07:00AM  miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-01-17 07:00AM  miRagen Therapeutics to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 11, 2017 GlobeNewswire
Jul-21-17 10:00AM  miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Jun-09-17 08:30AM  Should You Get Rid of Miragen Therapeutics (MGEN) Now? Zacks
Jun-08-17 07:00AM  miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma GlobeNewswire
Jun-05-17 07:00AM  miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides GlobeNewswire
Jun-01-17 07:00AM  miRagen Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-24-17 07:00AM  miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma GlobeNewswire
May-17-17 05:05PM  miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-10-17 04:05PM  miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-03-17 07:00AM  Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics GlobeNewswire
May-02-17 04:05PM  miRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results GlobeNewswire
Apr-27-17 04:05PM  miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions GlobeNewswire
Apr-26-17 07:00AM  miRagen Therapeutics to Participate in Two Investor Conferences in May GlobeNewswire
Apr-20-17 07:00AM  miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting GlobeNewswire
Mar-31-17 04:05PM  miRagen Therapeutics Provides Corporate Update GlobeNewswire
07:00AM  miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides GlobeNewswire
Feb-21-17 09:19AM  Why miRagen Therapeutics Shares Could See 60% Upside By 2018 Benzinga
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hughes Thomas E.DirectorOct 11Buy4.7710,00047,69712,827Oct 12 04:38 PM
Leverone Jason A.CFO, Treasurer & SecretaryAug 07Option Exercise0.5729,53016,83230,737Aug 09 04:18 PM